Affiliation:
1. State Key Laboratory of Natural Medicines, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, China
2. School of Pharmacy, Institutes of Integrative Medicine, Fudan University, Shanghai, China
Abstract
AbstractA novel acidic heteropolysaccharide (LCP-90-1) was isolated and purified from a traditional “heat-clearing” Chinese medicine, Lysimachia christinae Hance. LCP-90-1 (Mw,
20.65 kDa) was composed of Man, Rha, GlcA, Glc, Gal, and Ara, with relative molar ratios of 1.00: 3.00: 11.62: 1.31: 1.64: 5.24. The backbone consisted of 1,4-α-D-GlcpA,
1,4-α-D-Glcp, 1,4-β-L-Rhap, and 1,3,5-α-L-Araf, with three branches of β-D-Galp-(1 → 4)-β-L-Rhap-(1→,
α-L-Araf-(1→ and α-D-Manp-(1→ attached to the C-5 position of 1,3,5-α-L-Araf. LCP-90-1 exhibited potent anticomplement activity (CH50:
135.01 ± 0.68 µg/mL) in vitro, which was significantly enhanced with increased glucuronic acid (GlcA) content in its degradation production (LCP-90-1-A, CH50:
28.26 ± 0.39 µg/mL). However, both LCP-90-1 and LCP90-1-A were inactivated after reduction or complete acid hydrolysis. These observations indicated the important role of GlcA in LCP-90-1
and associated derivatives with respect to anticomplement activity. Similarly, compared with LCP-90-1, the antioxidant activity of LCP-90-1-A was also enhanced. Thus, polysaccharides with a
high content of GlcA might be important and effective substances of L. christinae.
Funder
Development Project of Shanghai Peak Disciplines-Integrative Medicine
National Key Research and Development Program of China
National Natural Science Foundation of China
Subject
Organic Chemistry,Complementary and alternative medicine,Drug Discovery,Pharmaceutical Science,Pharmacology,Molecular Medicine,Analytical Chemistry
Reference42 articles.
1. Complement deficiencies and dysregulation: Pathophysiological consequences, modern analysis, and clinical management;J S Braunstein;Mol Immunol,2019
2. Therapeutic targeting of the complement system: From rare diseases to pandemics;P Garred;Pharmacol Rev,2021
3. The complement system in systemic autoimmune disease;M Chen;J Autoimmun,2009
4. Advances in assay of complement function and activation;M Harboe;Adv Drug Deliv Rev,2011
5. Complement analysis in the era of targeted therapeutics;P Zoltán;Mol Immunol,2018